Management of IgE-mediated food allergy in the 21st century
- PMID: 36200952
- PMCID: PMC10092460
- DOI: 10.1111/cea.14241
Management of IgE-mediated food allergy in the 21st century
Abstract
The 21st century has seen the propulsion of research in the field of food allergy, which has driven real changes in the clinical approach. Allergen immunotherapy has been recommended for the active management of food allergy. Data have shown promising additional methods of treatment, including biologics. Efforts have been devoted to the risk stratification of food allergy and the standardization of the assessment of food-allergic severity. Alternative routes of administration of epinephrine are under investigation to minimize any mechanical issue and the fear of injections. Evidence-based guidelines have been published by the main international societies in the field of anaphylaxis and food allergy management and new updates are in preparation. In the coming years, treatment options that are currently in pre-clinical or early clinical evaluation will hopefully lead to safe and effective disease-modifying therapies for food allergy in clinical practice. The identification of reliable biomarkers and the standardization of definitions and measurement approaches, alongside a shared decision-making with patients and families, will be key for the development of personalized care and to help minimize the substantial burden of food allergy.
© 2022 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Conflict of interest statement
HB reports grant from National Institute of Allergy and Infectious Diseases (NIAID, NIH), and speaker honoraria from DBV Technologies, GSK and Sanofi. PB reports grant from Canadian Institutes of Health Research and the Fonds de Recherche du Québec ‐ Santé, Novartis, Sanofi, Regeneron and DBV technologies as well as personal fees from Novartis, Sanofi‐Genzyme, DBV technologies, Aralez, ALK, Pfizer, Astra‐Zeneca and Bausch Health outside the submitted work. SA has participated as an advisory board member, and/or consultant, and/or speaker for Aimmune, Novartis, and Ulrich outside the submitted work. AC and MG declare no conflicts of interest inherent to this paper.
Figures
References
-
- Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy. 2001;56(9):813‐824. - PubMed
-
- Logan K, Du Toit G, Giovannini M, Turcanu V, Lack G. Pediatric allergic diseases, food allergy, and oral tolerance. Annu Rev Cell Dev Biol. 2020;36:511‐528. - PubMed
-
- Chaaban MR, Warren Z, Baillargeon JG, Baillargeon G, Resto V, Kuo YF. Epidemiology and trends of anaphylaxis in the United States, 2004–2016. Int Forum Allergy Rhinol. 2019;9(6):607‐614. - PubMed
-
- Nwaru BI, Hickstein L, Panesar SS, et al. Prevalence of common food allergies in Europe: a systematic review and meta‐analysis. Allergy. 2014;69(8):992‐1007. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
